ライフサイエンスコーパス: ACEI

1 ACEI reduced glomerular capillary pressure, increased gl

2 ACEI reduced LVEDD (4.95+/-0.11 cm) and increased LVFS (

3 ACEI suppresses the development of MCT-induced PAH in ra

4 ACEI therapy was associated with a striking increase in

5 ACEI/ARB administration was associated with a significan

6 ACEI/ARB therapy had a significant negative effect on th

7 tic agents alone to three treatment arms: 1) ACEI therapy alone; 2) ACEI+BB; and 3) ACEI+BB+AldA.

8 rial pacing (240 bpm) for 3 weeks (n=9), (2) ACEI (benazeprilat, 0.187 mg x kg(-1) x d(-1)) and rapid

9 ee treatment arms: 1) ACEI therapy alone; 2) ACEI+BB; and 3) ACEI+BB+AldA.

10 rve is exhausted by hyperfiltration; and (2) ACEI restores the GFR response to glycine in established

11 ACEI and increased prednisone dose (n = 2), ACEI or ARB only (n = 2).

12 s: 1) ACEI therapy alone; 2) ACEI+BB; and 3) ACEI+BB+AldA.

13 ror [SE]: 2.7%), statin in 33.1% (SE: 2.4%), ACEI/ARB in 28.4% (SE: 2.0%), and cilostazol in 4.7% (SE

14 kg(-1) x d(-1)) and rapid pacing (n=9), (4) ACEI and AT1 Ang II receptor blockade (benazeprilat/vals

15 ia; 12 were treated with: rituximab (n = 8), ACEI and increased prednisone dose (n = 2), ACEI or ARB

16 3.9), statins (OR: 2.6; 95% CI: 1.8 to 3.9), ACEI/ARB (OR: 2.6; 95% CI: 1.8 to 3.9), and smoking cess

17 , adjusted OR: 8.22 (95% CI: 6.20 to 10.90); ACEI/ARBs, adjusted OR: 5.80 (95% CI: 2.56 to 13.16); p

18 809 (an AT(1) blocker; AT(1)), enalapril (an ACEI), and hydralazine (a vasodilator) were administered

19 ssess the factors associated with filling an ACEI prescription in the 30 days postdischarge and the p

20 statin (7.1% vs. 4.8%, p < 0.0001) or for an ACEI/ARB (29.1% vs. 22.4%, p < 0.0001), but similar prop

21 this study was to compare the effects of an ACEI (enalapril) and AT1RA (losartan), alone or in combi

22 hether the expected biochemical effect of an ACEI is present in the patient's bloodstream.

23 % started therapy with a statin, 11% with an ACEI/ARB, and 5% with both.

24 The cost-savings in the ACEI and ACEI+BB cohorts compared to that with diuretics alone we

25 Treatment with ACEI and ACEI+BB strictly dominated treatment with diuretics only

26 ifferences in renoprotection between ARB and ACEI.

27 High-dose AT1RA and ACEI markedly decreased progression of sclerosis, with -

28 io (ICER) of ACEI+BB+AldA versus ACEI+BB and ACEI+BB versus ACEI was <$1,500 per quality-adjusted lif

29 role of combining digoxin with diuretic and ACEI in the initial management of patients with heart fa

30 patients who continued digoxin, diuretic and ACEI therapy (4.7%) compared to 18 of the 42 patients (1

31 (ACEI and diuretic, or digoxin, diuretic and ACEI) trials were analyzed.

32 In addition, GABA and ACEI activity of LSF increased in a time-dependent manne

33 on is associated with lower serum lipids and ACEI in patients after TX.

34 detected between baseline urine protein and ACEI therapy (P = 0.003).

35 s, goal doses of beta-blockers, statins, and ACEI/ARBs were achieved in only 12%, 26%, and 32% of eli

36 kers, HR, 0.61 and 95% CI, 0.57 to 0.65; and ACEIs among heart failure patients, HR, 0.75 and 95% CI,

37 nvestigated the effects of AT(1) antagonism, ACEI, and their combination in a well-characterized ovin

38 ose AT1RA, high-dose ACEI, and varying AT1RA+ACEI combinations.

39 action, addition of eplerenone to background ACEI or ARB therapy attenuates the progressive decline i

40 Adjusting for the use of statins, BBs, ACEIs/ARBs, and antiplatelet drugs after discharge compl

41 orded filled prescriptions for statins, BBs, ACEIs/ARBs, or antiplatelet agents within 30 days after

42 a dose-dependent inverse association between ACEI use and the risk for developing ALS.

43 The association between ACEI/ARB treatment and outcomes (mortality, myocardial i

44 Most head-to-head comparisons between ACEI and ARB have yielded comparable CV protective effec

45 dose-response relationship was found between ACEI dose and HCT.

46 terone system inhibition with dual blockade, ACEI and angiotensin receptor antagonists, on renal volu

47 re are ample data to support a role for both ACEI and ARB to prevent the progression from microalbumi

48 e exception occurred in patients taking both ACEI and BB as co-treatment, in whom the decrease in LVI

49 ive ACEI than were nondiabetic patients, but ACEI use was quite low even among diabetic patients with

50 expression of p21 and eNOS was modulated by ACEI treatment in a rat model.

51 of nondialysis-dependent patients with CKD, ACEI/ARB administration was associated with greater surv

52 ng) II receptor blockade alone, and combined ACEI and AT1 Ang II receptor blockade on LV function, sy

53 bitor (ACEI) who were randomized to continue ACEI until the morning of surgery (ACEI group, n=19) or

54 2; P = .001) for the group with a cumulative ACEI use of greater than 449.5 cDDD.

55 l actions than ACE inhibition plus diuretic (ACEI+D) in congestive heart failure.

56 erimental congestive heart failure than does ACEI+D.

57 I (sACEI; ramipril 10 mg/d, n=14), high-dose ACEI (hACEI; ramipril 20 mg/d, n=8), AT(1) blockade (los

58 Compared with low dose, high-dose ACEI or ARBs decreased all-cause mortality modestly (rel

59 treatment (CONT), high-dose AT1RA, high-dose ACEI, and varying AT1RA+ACEI combinations.

60 ecreased by all treatments, except high-dose ACEI, which showed persistent proteinuria.

61 s: no therapy (control, n=12), standard-dose ACEI (sACEI; ramipril 10 mg/d, n=14), high-dose ACEI (hA

62 in assay and DNA laddering before and during ACEI therapy.

63 th risk is continuous but is lost with early ACEI therapy.

64 Beyond a simple antihypertensive effect, ACEIs have been shown to reduce the rates of myocardial

65 ted that valsartan therapy taken with either ACEI or BB reversed LV remodeling.

66 mposite outcome of AKI and mortality favored ACEI/ARB treatment.

67 ockers only, 0.98 (95% CI: 0.91 to 1.07) for ACEI/ARBs and statins only, 1.17 (95% CI: 1.10 to 1.25)

68 ssion ratios than patients receiving PCI for ACEI/ARBs (69.4% vs. 77.8%, p < 0.0001), beta-blockers (

69 Except for ACEIs among patients without heart failure, consistent u

70 Patients with a discharge order for ACEIs were more likely to fill a prescription within 30

71 st, for patients with no discharge order for ACEIs, only 12.7%/12.0% (depressed EF/total cohort) had

72 In ACEI-treated diabetics, the SNGFR response to glycine wa

73 incidence of major cardiovascular events in ACEI-treated recipients.

74 incidence of major cardiovascular events in ACEI-treated recipients.

75 e Telmisartan Randomized Assessment Study in ACEI Intolerant Subjects With Cardiovascular Disease (TR

76 to determine the effects of ACE inhibition (ACEI) alone, AT1 angiotensin (Ang) II receptor blockade

77 ACE inhibition (ACEI) attenuates post-myocardial infarction (MI) LV remo

78 s, angiotensin-converting enzyme inhibition (ACEI) restores the effect of glycine on GFR.

79 rolled clinical trials (RCT), ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB) therapy hav

80 ACE inhibitor (ACEI) may have beneficial effects in treating PAH, but i

81 vity in 31 patients taking an ACE inhibitor (ACEI) who were randomized to continue ACEI until the mor

82 giotensin-converting enzyme (ACE) inhibitor (ACEI) therapy in chronic heart failure.

83 her angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) should be u

84 ing angiotensin-converting enzyme inhibitor (ACEI) and/or beta-blocker (BB) were randomized into vals

85 and angiotensin-converting enzyme inhibitor (ACEI) compared to other combinations of these drugs in p

86 or angiotensin-converting enzyme inhibitor (ACEI) has demonstrated particular promise in patients wi

87 ith angiotensin-converting enzyme inhibitor (ACEI) monotherapy.

88 er, angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB), and diur

89 ing angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor antagonist (ARB) therapy,

90 ved angiotensin-converting enzyme inhibitor (ACEI) therapy at the end of the trial and were followed

91 rom angiotensin-converting enzyme inhibitor (ACEI) therapy when they are at low risk for disease prog

92 ent angiotensin-converting enzyme inhibitor (ACEI) use after heart failure (HF) hospitalization.

93 r angiotensin I converting enzyme inhibitor (ACEI) were investigated.

94 of angiotensin-converting enzyme inhibitor (ACEI), beta-blocker (BB), and aldosterone antagonist (Al

95 an angiotensin-converting enzyme inhibitor (ACEI).

96 een angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) use and mortali

97 Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor antagonists (AT1RA) sl

98 s, angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB).

99 en angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) doses on o

100 Angiotensin converting enzyme inhibitors (ACEI) are efficacious in lowering the hematocrit of pati

101 Angiotensin-converting enzyme inhibitors (ACEI) are the treatment of choice in PTE, but their mech

102 Angiotensin-converting enzyme inhibitors (ACEI) have become the treatment of choice for posttransp

103 th angiotensin-converting enzyme inhibitors (ACEI) is considered a standard therapeutic intervention

104 Angiotensin II converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) presumab

105 s, angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) are general

106 Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) initiated a

107 er angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).

108 le angiotensin-converting enzyme inhibitors (ACEI) to downregulate the renin-angiotensin system.

109 ng angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), beta-blocker

110 on angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), beta-blocke

111 of angiotensin converting enzyme inhibitors (ACEI).

112 nd angiotensin-converting enzyme inhibitors (ACEI)/angiotensin II receptor blockers (ARBs) at dischar

113 of angiotensin-converting enzyme inhibitors (ACEI, P < .05), and to have a lower volumetric remodelin

114 ACE inhibitors (ACEIs) and angiotensin II type 1 (AT(1)) receptor blocke

115 th angiotensin-converting enzyme inhibitors (ACEIs) improves MPR in patients with hypertension by pot

116 of angiotensin-converting enzyme inhibitors (ACEIs) in coronary artery bypass graft surgery has been

117 of angiotensin-converting enzyme inhibitors (ACEIs) in patients with coronary heart disease and prese

118 of angiotensin-converting enzyme inhibitors (ACEIs) in those with and without heart failure.

119 Angiotensin-converting enzyme inhibitors (ACEIs) may retard the development of CAV but have not be

120 of angiotensin-converting enzyme inhibitors (ACEIs) on hematocrit values in those with heart failure,

121 Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are widel

122 Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are widel

123 of angiotensin-converting enzyme inhibitors (ACEIs) potentially decreased amyotrophic lateral scleros

124 ), angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin-II receptor blockers (ARBs) have

125 to angiotensin-converting enzyme inhibitors (ACEIs), calcium antagonists (CCBs) and alpha-blockers in

126 to angiotensin-converting enzyme inhibitors (ACEIs), single-nucleotide polymorphisms (SNPs) in the an

127 to angiotensin-converting enzyme inhibitors (ACEIs).

128 of angiotensin-converting enzyme inhibitors (ACEIs).

129 s, angiotensin-converting enzyme inhibitors [ACEIs] or angiotensin receptor blockers [ARBs], and cilo

130 n (angiotensin-converting enzyme inhibitors [ACEIs], angiotensin receptor blockers [ARBs], and beta-b

131 angiotensin I-converting enzyme inhibitory (ACEI) activities than SSF.

132 nd angiotensin converting enzyme inhibitory (ACEI) activity (>90%).

133 ened awareness of the phenomenon of isolated ACEI-associated visceral angioedema is necessary given t

134 Like ACEI, ARB are effective antihypertensive and antiprotein

135 MCT(+)/ACEI(+) rats showed a preserved right ventricular morpho

136 ther group did not receive enalapril (MCT(+)/ACEI(-) rats).

137 21 and eNOS expression in the lung in MCT(+)/ACEI(-) rats, whereas their expression was preserved wit

138 owed right ventricular hypertrophy in MCT(+)/ACEI(-) rats.

139 ncomitantly with enalapril treatment (MCT(+)/ACEI(+) rats), and the other group did not receive enala

140 For NDTI, ACEI use in CHF increased from 24% in 1990 to 36% in 199

141 l, 923 (21.8%); addition, 343 (8.1%); and no ACEI, 2043 (48.4%).

142 Continuous treatment with ACEI versus no ACEI was associated with substantive reductions of risk

143 CEI de novo postoperatively compared with no ACEI therapy was also associated with a significant redu

144 o discontinue it 48 hours before surgery (No-ACEI group, n=12).

145 line to POD1 (P=0.009) were higher in the No-ACEI group (from 17.0+/-5.0 to 48.7+/-8.8 ng/mL) versus

146 tly greater in the ACEI group than in the No-ACEI group (P=0.030).

147 subgroup originally randomly assigned to non-ACEI therapy.

148 Furthermore, continuation of ACEI or de novo ACEI therapy early after cardiac surgery is associated w

149 The 3-year mortality was 19.8% (17.4% of ACEI/ARB users and 25.4% of nonusers).

150 at biopsy in 62% of AT1RA-treated and 57% of ACEI-treated rats.

151 nesis of PTE and the mechanisms of action of ACEI remain unclear.

152 Addition of ACEI de novo postoperatively compared with no ACEI thera

153 sufficient evidence about the association of ACEI or ARBs with mortality in patients with CKD.

154 We examined the association of ACEI/ARB administration with all-cause mortality in pati

155 The association of ACEI/ARB treatment with lower risk of mortality was pres

156 was no variation in the degree of benefit of ACEI therapy (P = 0.93 for the treatment x risk interact

157 However, there was no benefit of ACEI therapy among patients with proteinuria <500 mg/d,

158 We report the first known case of ACEI-associated visceral angioedema occurring in a liver

159 a-analysis suggested that the combination of ACEI+BB+MRA was associated with a 56% reduction in morta

160 Furthermore, continuation of ACEI or de novo ACEI therapy early after cardiac surgery

161 rformed in diabetics, diabetics after 5 d of ACEI (enalapril in the drinking water), and weight-match

162 udy was to investigate the effect of dose of ACEI and ARBs on outcomes and drug discontinuation in pa

163 , compared with lower doses, higher doses of ACEI and ARB significantly though modestly improved the

164 ontrolled trials that compared high doses of ACEI or ARB against low doses among patients with HF wit

165 enylyl cyclase (AC) by testing the effect of ACEI and ARB in mice with juxtaglomerular cell-specific

166 ase progression, but the treatment effect of ACEI does not vary across risk strata.

167 Although the CV protective effect of ACEI in high-risk populations is widely appreciated, whe

168 t, reversed the basal vasodilatory effect of ACEI in the pulmonary vasculature.

169 In this report, the effect of ACEI on CD34+ erythroid precursor apoptosis was studied,

170 The effect of ACEI to decrease hematocrit in patients with PTE may be

171 have demonstrated a CV protective effect of ACEI when compared with other active agents in patients

172 merular hemodynamic basis for this effect of ACEI, micropuncture studies were performed in male Wista

173 , ARB lack the kinin-potentiating effects of ACEI.

174 cremental cost-effectiveness ratio (ICER) of ACEI+BB+AldA versus ACEI+BB and ACEI+BB versus ACEI was

175 In particular, the low likelihood of ACEI/ARB after coronary artery bypass grafting surgery o

176 with time after TX, hypertension, nonuse of ACEI, donor age, and changes in total cholesterol and tr

177 Postoperatively, the pattern of ACEI use yielded 4 groups: continuation, 915 (21.7%); wi

178 ysis was used to calculate the propensity of ACEI/ARB initiation in 141,413 U.S. veterans with nondia

179 lure (n = 39) were randomized to regimens of ACEI nonadherence for one week, ACEI adherence for one w

180 omes were anticipated to be equal to that of ACEI.

181 On the other hand, continuous treatment of ACEI versus withdrawal of ACEI was associated with decre

182 ify randomized, placebo-controlled trials of ACEI use in patients with CAD and preserved LV systolic

183 Our study suggests that withdrawal of ACEI treatment after coronary artery bypass graft surger

184 nuous treatment of ACEI versus withdrawal of ACEI was associated with decreased risk of the composite

185 flicting evidence concerning the benefits of ACEIs in patients with coronary artery disease (CAD) and

186 -analysis shows a modest favorable effect of ACEIs on the outcome of patients with CAD and preserved

187 Use of ACEIs exhibited a dose-dependent inverse association wit

188 The use of ACEIs in chronic heart failure gives us a unique opportu

189 Use of ACEIs was analyzed using a conditional logistic regressi

190 Use of ACEIs was associated with a decrease in cardiovascular m

191 (p=0.009), to 23 of the 93 patients (25%) on ACEI and diuretic therapy (p=0.001) and to 18 of the 46

192 d discharge and continuous follow-up data on ACEI/ARB use among AMI survivors (2006 to 2009) included

193 Patients on ACEI had significantly lower HCT (P = 0.005) compared wi

194 st to control subjects, patients with PTE on ACEI showed a significant decrease in IGF-1 levels and a

195 essures to a greater level than OMA alone or ACEI+D.

196 with a combination of diuretic and an ARB or ACEI.

197 els estimated the causal effect of statin or ACEI/ARB initiation on neurocognitive function; initial

198 e were seen in single domains with statin or ACEI/ARB therapy, we did not find consistent evidence th

199 ohort participants not receiving a statin or ACEI/ARB within 30 days of first neurologic assessment (

200 not find consistent evidence that statins or ACEI/ARB have an effect on global neurocognitive functio

201 Among heart failure patients, ACEI use was 51% in 2002 and consistent use, 39%.

202 he exception of ARB monotherapy and ARB plus ACEI.

203 Preoperative ACEI attenuates the increase in PAI-1 after CABG, sugges

204 hrologists were not more likely to prescribe ACEI than were primary care physicians.

205 0.65-1.07; P = .15) for the group prescribed ACEIs lower than 449.5 of the cDDD and 0.43 cDDD (95% CI

206 In PTE, ACEI-related increase in erythroid progenitor apoptosis

207 alone or digoxin and diuretic) and RADIANCE (ACEI and diuretic, or digoxin, diuretic and ACEI) trials

208 to block the renin-angiotensin system (RAS), ACEI and AT1RA act at different sites in the RAS cascade

209 iabetic patients were more likely to receive ACEI than were nondiabetic patients, but ACEI use was qu

210 nic kidney disease), 49,682 (81.7%) received ACEI/ARB with an increase in the rate of treatment over

211 ransplants analyzed, 15,250 (38.9%) received ACEI/ARB and 24,001 (61.1%) received other antihypertens

212 ransplants analyzed, 15,250 (38.9%) received ACEI/ARB and 24,001 (61.1%) received other antihypertens

213 r death was similar in patients who received ACEI/ARB therapy or other antihypertensive treatment ove

214 r death was similar in patients who received ACEI/ARB therapy or other antihypertensive treatment ove

215 Among those originally receiving ACEI therapy, however, the event rate was uniformly low

216 The cohort included 1838 patients receiving ACEI therapy before surgery and 2386 (56.5%) without ACE

217 th in kidney transplant recipients receiving ACEI/ARB or other antihypertensive medications is virtua

218 th in kidney transplant recipients receiving ACEI/ARB or other antihypertensive medications is virtua

219 rt Association class I guideline-recommended ACEI/ARB therapy, and the use varies by patient factors.

220 patients without heart failure, 39% reported ACEI use in 2002; consistent use was 20%.

221 of ARB that can be compared with large-scale ACEI clinical trials have yet to be completed.

222 In normal control subjects, ACEI therapy was associated with a fall in Hct but no ch

223 continue ACEI until the morning of surgery (ACEI group, n=19) or to discontinue it 48 hours before s

224 e was associated with lower IOP and systemic ACEI, ARB, statin, and sulfonylurea use was associated w

225 ents with HF who are discharged while taking ACEIs, there is a significant decline in use after disch

226 Use of this risk model for targeting ACEI therapy was also compared with a strategy based on

227 at ARNI monotherapy is more efficacious than ACEI or ARB monotherapy.

228 nsin II at the cellular level, implying that ACEI and ARB may work by reducing intracellular calcium.

229 omized clinical investigation indicates that ACEI and a BP goal of 120/80 mmHg are associated in a 7-

230 It was shown previously that ACEI added directly to cultures of erythroid precursors

231 ated pulmonary perfusion studies showed that ACEI significantly upregulated NO production, as measure

232 nts with polycythemia have demonstrated that ACEIs are effective in lowering hematocrit values.

233 The ACEI captopril and quinaprilate and the ARB candesartan

234 The ACEI was effective but to a lesser extent.

235 opoietin (Ep), angiotensin II (AII), and the ACEI enalaprilat on the in vitro proliferation of erythr

236 ogenitor apoptosis may partially explain the ACEI-associated decrease in Hct.

237 The cost-savings in the ACEI and ACEI+BB cohorts compared to that with diuretics

238 PA activity was significantly greater in the ACEI group than in the No-ACEI group (P=0.030).

239 costs and lower hospitalization rates in the ACEI+BB+AldA arm resulted in greater cost-savings.

240 study tested the safety and efficacy of the ACEI ramipril on the development of CAV early after HT.

241 In the early and late studies, the ACEI reduced myocyte volume.

242 ejection fraction (LVEF) and similar to the ACEI in preventing heart failure with impaired LVEF.

243 m 17.0+/-5.0 to 48.7+/-8.8 ng/mL) versus the ACEI group (from 19.9+/-3.4 to 33.1+/-6.2 ng/mL).

244 The ACEIs have been shown to improve outcomes in patients wi

245 Thus, ACEIs, but not ARBs, might be effective in repairing the

246 ns of OMA alone and with diuretic (OMA+D) to ACEI+D in a model of pacing-induced congestive heart fai

247 There were 16,772 patients randomized to ACEI and 16,728 patients randomized to placebo.

248 ed for their association with BP response to ACEI in Chinese patients with hypertension in a 2-stage

249 associated with BP reduction in response to ACEI therapy in hypertensive Chinese patients.

250 The total variations in response to ACEI therapy that were explained by the AGT SNP and AGTR

251 kers to predict the hypertensive response to ACEI therapy.

252 ialysis CKD who were previously unexposed to ACEI/ARB treatment.

253 When compared with patients who did not use ACEIs, the adjusted odds ratios were 0.83 (95% CI, 0.65-

254 chance for developing ALS in people who used ACEIs greater than 449.5 cDDD in 4 years.

255 tiveness ratio (ICER) of ACEI+BB+AldA versus ACEI+BB and ACEI+BB versus ACEI was <$1,500 per quality-

256 EI+BB+AldA versus ACEI+BB and ACEI+BB versus ACEI was <$1,500 per quality-adjusted life-year.

257 regimens of ACEI nonadherence for one week, ACEI adherence for one week or two versions of partial a

258 This study sought to investigate whether ACEI/ARB treatment after AMI is associated with better o

259 ing graft were analyzed according to whether ACEI/ARB or other antihypertensive therapy (excluding di

260 ing graft were analyzed according to whether ACEI/ARB or other antihypertensive therapy (excluding di

261 Yet the extent to which ACEI/ARB therapy is applied in patients with acute coron

262 g II blockade group and improved by 25% with ACEI and increased by 54% with combined treatment.

263 ozen experimental studies comparing ARB with ACEI suggest that the two classes of drugs share similar

264 DIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidi

265 DIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidi

266 F trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidi

267 ) in the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidi

268 In the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidi

269 F trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidi

270 e in the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidi

271 DIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidi

272 DIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidi

273 (1)) antagonism alone or in combination with ACEI are unclear.

274 point, protection has been demonstrated with ACEI only for type 1 but not type 2 diabetes.

275 ls showed no inhibition of BFU-E growth with ACEI.

276 categories but was significantly higher with ACEI/ARB treatment.

277 y and aldosterone immediately increased with ACEI+D, whereas OMA+D resulted in higher plasma renin ac

278 iotensin-receptor-neprilysin inhibitor) with ACEI (angiotensin-converting enzyme inhibitor) to Determ

279 iotensin Receptor-Neprilysin Inhibitor] With ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determ

280 iotensin Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determ

281 iotensin Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determ

282 Glomerular filtration rate was lower with ACEI+D than with either OMA group.

283 al actions comparable to those observed with ACEI+D that can be explained by potentiation of natriure

284 dosterone with OMA alone such as occurs with ACEI+D and OMA+D.

285 drenomedullin, and cGMP excretions than with ACEI+D.

286 vival was observed for patients treated with ACEI/ARB (3-year hazard ratio: 0.80; 95% confidence inte

287 Overall, those treated with ACEI/ARB also had lower 3-year risk for myocardial infar

288 tal, 45,697 patients (71%) were treated with ACEI/ARB.

289 Treatment with ACEI and ACEI+BB strictly dominated treatment with diure

290 y a role in HIV-AN, and early treatment with ACEI may be beneficial in HIV-AN.

291 Continuous treatment with ACEI versus no ACEI was associated with substantive redu

292 ork meta-analysis showed that treatment with ACEI, ARB, BB, MRA, and ARNI and their combinations were

293 Treatment with ACEI/ARB after AMI was associated with improved long-ter

294 ssion analysis confirmed that treatment with ACEI/ARB did not confer a beneficial effect beyond that

295 ssion analysis confirmed that treatment with ACEI/ARB did not confer a beneficial effect beyond that

296 Patients not discharged with ACEIs are unlikely to be started as outpatients.

297 F/total cohort) of survivors discharged with ACEIs had filled a prescription by 30 days postdischarge

298 55% of the total cohort were discharged with ACEIs.

299 Assuring therapy with ACEIs at discharge after HF hospitalization is a key Med

300 rapy before surgery and 2386 (56.5%) without ACEI exposure.